

**Supplementary table 1. Baseline characteristics of high and low NLR patients.**

<b>Variable</b>	<b>Total (n = 293)</b>	<b>NLR &lt; 4.9 (n = 162)</b>	<b>NLR ≥ 4.9 (n = 131)</b>	<b>P</b>
Age, M (Q <sub>1</sub> , Q <sub>3</sub> )	59.0 (49.0 - 67.0)	60.0 (50.0 - 67.0)	59.0 (48.5 - 67.0)	0.692
Gender, n (%)				0.314
male	174 (59.4)	92 (56.8)	82 (62.6)	
female	119 (40.6)	70 (43.2)	49 (37.4)	
Etiology				0.221
HBV	169 (57.7)	88 (54.3)	81 (61.8)	
AIH	43 (14.7)	25 (15.4)	18 (13.7)	
schistosomiasis	41 (14.0)	26 (16.1)	15 (11.5)	
others	40 (13.7)	23 (14.2)	17 (13.0)	
Early TIPS	148 (50.5)	70 (43.2)	78 (59.5)	0.005





Ascites, n (%)	155 (52.9)	86 (53.1)	69 (52.7)	0.944
Portal vein thrombosis, n (%)	81 (27.7)	44 (27.2)	37 (28.2)	0.837
Diabetes, n (%)	68 (23.2)	38 (23.5)	30 (22.9)	0.911
Splenectomy, n (%)	40 (13.7)	26 (16.1)	14 (10.7)	0.184
Presence of gastric varices, n (%)	53 (18.1)	29 (17.9)	24 (18.3)	0.926
Child-Pugh score, M (Q <sub>1</sub> , Q <sub>3</sub> )	7.0 (6.0 - 9.0)	7.0 (6.0 - 8.0)	7.0 (6.0 - 9.0)	0.624
Child-Pugh grade, n (%)				0.091
A	101 (34.5)	54 (33.3)	47 (35.9)	
B	159 (54.3)	95 (58.6)	64 (48.9)	
C	33 (11.3)	13 (8.0)	20 (15.3)	
MELD score, M (Q <sub>1</sub> , Q <sub>3</sub> )	11.0 (9.0 - 13.0)	10.0 (9.0 - 12.0)	11.0 (9.0 - 13.0)	0.111
Total bilirubin (μmol/L), M (Q <sub>1</sub> , Q <sub>3</sub> )	21.3 (15.4 - 29.9)	20.3 (14.9 - 28.6)	22.4 (16.0 - 31.3)	0.146

Albumin (g/L), M (Q <sub>1</sub> , Q <sub>3</sub> )	30.7 (26.9 - 34.3)	30.9 (27.4 - 34.3)	30.4 (26.5 - 33.6)	0.245
Pre-albumin (g/L), M (Q <sub>1</sub> , Q <sub>3</sub> )	88.8 (63.2 - 110.1)	89.5 (66.6 - 109.6)	87.2 (60.0 - 112.3)	0.635
Creatinine (μmol/L), M (Q <sub>1</sub> , Q <sub>3</sub> )	62.8 (53.0 - 74.4)	63.2 (54.0 - 73.6)	62.0 (51.7 - 76.2)	0.558
Prothrombin time (S), M (Q <sub>1</sub> , Q <sub>3</sub> )	15.9 (14.3 - 17.3)	15.4 (14.1 - 17.0)	16.1 (14.7 - 17.7)	0.016
International normalized ratio, M (Q <sub>1</sub> , Q <sub>3</sub> )	1.34 (1.21 - 1.48)	1.30 (1.19 - 1.47)	1.37 (1.23 - 1.48)	0.072
Platelet count (×10 <sup>9</sup> /L), M (Q <sub>1</sub> , Q <sub>3</sub> )	69.0 (48.0 - 102.0)	67.0 (48.3 - 103.8)	70.0 (47.5 - 101.0)	0.754
White blood cell (×10 <sup>9</sup> /L), M (Q <sub>1</sub> , Q <sub>3</sub> )	4.9 (2.9 - 7.6)	3.9 (2.4 - 5.8)	6.6 (4.0 - 10.4)	< 0.001
Neutrophil count (×10 <sup>9</sup> /L), M (Q <sub>1</sub> , Q <sub>3</sub> )	3.0 (1.7 - 5.5)	2.0 (1.3 - 3.1)	5.3 (3.4 - 7.9)	< 0.001
Lymphocyte count (×10 <sup>9</sup> /L), M (Q <sub>1</sub> , Q <sub>3</sub> )	0.7 (0.5 - 1.0)	0.8 (0.6 - 1.3)	0.5 (0.4 - 0.8)	< 0.001
NLR, M (Q <sub>1</sub> , Q <sub>3</sub> )	4.4 (2.5 - 9.2)	2.6 (1.7 - 3.4)	9.7 (6.6 - 13.8)	< 0.001
Pre-TIPS PPG (mmHg), M (Q <sub>1</sub> , Q <sub>3</sub> )	26.0 (22.0 - 32.0)	26.5 (22.0 - 33.0)	26.0 (22.0 - 31.0)	0.690
Portal vein puncture, n (%)				0.002


left portal vein	185 (63.1)	88 (54.3)	97 (74.1)
right portal vein	51 (17.4)	37 (22.8)	14 (10.7)
main portal vein	57 (19.5)	37 (22.8)	20 (15.3)

---

Note: Data are expressed as median (IQR) or *n* (%). Abbreviations: HBV, hepatitis B virus; AIH, autoimmune hepatitis; MELD, model for end-stage liver disease; NLR, neutrophil-to-lymphocyte ratio; TIPS, transjugular intrahepatic portosystemic shunt; PPG, portal pressure gradient.



### Spearman Correlation with Death



### **Figure legends for supplementary figures**

**Supplementary Figure 1:** Distribution of NLR in different subgroups. (A) Age; (B) Diabetes; (C) Ascites; (D) PVT. NLR, neutrophil-to-lymphocyte ratio; PVT, portal vein thrombosis.

**Supplementary Figure 2:** Heatmap of Spearman correlation coefficients between NLR and the risk of mortality. The correlations between NLR values at 1 month, 3 months, 6 months, and 12 months post-TIPS placement and the risk of mortality were 0.107, 0.016, -0.021, and 0.036, respectively. NLR, neutrophil-to-lymphocyte ratio; TIPS, transjugular intrahepatic portosystemic shunt.